Mindpeak Announces CE-IVD Mark for Artificial Intelligence Breast Cancer Cell Quantification

HAMBURG, Germany--(BUSINESS WIRE)--Mindpeak, a European leader in computational pathology, announced today that it has received CE-IVD Mark for BreastIHC, an Artificial Intelligence software that detects and quantifies breast cancer cells, for primary diagnosis. The CE-IVD Mark makes the software available to pathology practices across Europe and helps overcome the challenge of an increasing demand for cancer diagnostics. The detection and quantification of immunohistochemically stained breast tumor cells is one of the most critical tasks for a pathologist as the diagnosis directly impacts the treatment decision for the patient. BreastIHC is a plug-and-play solution that enables pathology laboratories to immediately detect, classify and quantify breast cancer cells without the need for complex set-up and calibration procedures. BreastIHC classifies cells into positively stained tumor and unstained tumor cells.